The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 04, 2014
Filed:
Oct. 29, 2010
Peter Peizhi Luo, Lansdale, PA (US);
Kevin Caili Wangr, Lansdale, PA (US);
Pingyu Zhong, Blue Bell, PA (US);
Mark Hsieh, Jenkintown, PA (US);
Yan LI, San Jose, CA (US);
Xinwei Wang, Germantown, MD (US);
Feng Dong, Lansdale, PA (US);
Andrei Golosov, Cambridge, MA (US);
Yan NI, Westfield, NJ (US);
Weirong Wang, Harleysville, PA (US);
Laurence B. Peterson, Westfield, NJ (US);
Rose Cubbon, Fanwood, NJ (US);
Sujata Sharma, Eagleville, PA (US);
Jon Condra, Doylestown, PA (US);
Jun LU, Lansdale, PA (US);
Gopalakrishnan Parthasarathy, Hillsborough, NJ (US);
Stephen Soisson, Hillsborough, NJ (US);
Noel Byrne, Doylestown, PA (US);
Peter Peizhi Luo, Lansdale, PA (US);
Kevin Caili Wangr, Lansdale, PA (US);
Pingyu Zhong, Blue Bell, PA (US);
Mark Hsieh, Jenkintown, PA (US);
Yan Li, San Jose, CA (US);
Xinwei Wang, Germantown, MD (US);
Feng Dong, Lansdale, PA (US);
Andrei Golosov, Cambridge, MA (US);
Yan Ni, Westfield, NJ (US);
Weirong Wang, Harleysville, PA (US);
Laurence B. Peterson, Westfield, NJ (US);
Rose Cubbon, Fanwood, NJ (US);
Sujata Sharma, Eagleville, PA (US);
Jon Condra, Doylestown, PA (US);
Jun Lu, Lansdale, PA (US);
Gopalakrishnan Parthasarathy, Hillsborough, NJ (US);
Stephen Soisson, Hillsborough, NJ (US);
Noel Byrne, Doylestown, PA (US);
Merck Sharp & Dohme Corp., Rahway, NJ (US);
Abstract
Antagonists of human proprotein convertase subtilisin-kexin type 9 ('PCSK9') are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.